Can lactoferrin be elevated in stool while calprotectin levels remain normal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discordant Fecal Biomarkers: Lactoferrin Elevation with Normal Calprotectin

Yes, lactoferrin can be elevated in stool while calprotectin levels remain normal, which creates diagnostic uncertainty that typically warrants further investigation. 1

Diagnostic Performance of Fecal Biomarkers

  • Fecal lactoferrin has a sensitivity of 83% (95% CI, 72%-90%) and specificity of 75% (95% CI, 59%-87%) for detecting moderate to severe endoscopic inflammation in inflammatory bowel disease (IBD) 2
  • Fecal calprotectin at a cutoff of 150 ± 50 mg/g has a sensitivity of 71% (95% CI, 62%-78%) and specificity of 69% (95% CI, 62%-75%) for detecting moderate to severe endoscopic inflammation 2
  • Despite similar overall diagnostic accuracy (80-100% for both markers), these biomarkers can show discordant results in approximately 10% of cases 3, 4

Clinical Significance of Discordant Results

  • Discordance between normal calprotectin and elevated lactoferrin may reflect segmental disease that might be missed by calprotectin alone 1
  • Different clinical specialties use these markers differently - gastroenterologists tend to order calprotectin more frequently for abdominal pain, while primary care providers often order lactoferrin in the context of acute diarrhea 5
  • The proportion of calprotectin orders has increased from 60% to nearly 90% compared to lactoferrin over the past decade, though the tests are not treated as equivalent by clinicians 5

Management Recommendations for Discordant Results

  • For patients with normal calprotectin but elevated lactoferrin and mild symptoms, endoscopic assessment is recommended rather than empiric treatment adjustment 1
  • For asymptomatic patients with this discordant pattern, repeat biomarker measurement in 3-6 months is suggested before proceeding to endoscopy 1
  • If endoscopy confirms inflammation despite normal calprotectin, treatment should be adjusted based on endoscopic findings, and both biomarkers should continue to be monitored to establish which correlates better with the patient's disease activity 1

Potential Causes of Discordant Results

  • Ileal Crohn's disease may show poor correlation between fecal markers and ileal inflammation - studies have shown that ileal endoscopic scores and histological findings failed to correlate with fecal markers 6
  • Non-IBD conditions like Clostridium difficile infection can elevate both markers but with significant inter-individual variability 7
  • Medications, particularly NSAIDs used in the past 6 weeks, can affect biomarker levels and should be considered when interpreting discordant results 1
  • Different collection and processing methods can affect stability and measurement of these biomarkers 8

Practical Approach to Discordant Results

  • Rule out infections first, particularly C. difficile and other enteric pathogens, as these can cause elevated inflammatory markers 2
  • For patients with moderate to severe symptoms and elevated lactoferrin (even with normal calprotectin), consider treatment adjustment without routine endoscopic assessment 2
  • For patients with mild symptoms and discordant markers, proceed with endoscopic assessment to confirm the presence or absence of inflammation 2, 1
  • If endoscopy shows no inflammation despite elevated lactoferrin, consider other causes such as infections or medications, and repeat lactoferrin testing in 3-6 months 1

References

Guideline

Management of Discordant Biomarkers in Inflammatory Bowel Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fecal markers: calprotectin and lactoferrin.

Gastroenterology clinics of North America, 2012

Research

Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease?

Clinica chimica acta; international journal of clinical chemistry, 2020

Guideline

Management of Elevated Faecal Calprotectin in Acute Settings

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.